The PPARγ agonist rosiglitazone, which induces PGC-1α expression, may ameliorate podocyte impairment, GBM thickening, and kidney fibrosis in DN (Zhang et al., 2018). This evidence concerns the gene PPARGC1A and liver dysplastic nodule.